Invokana Lawsuit Plaintiffs Gain Support From FDA Safety Announcements Regarding Concerning Side Effects

April 27, 2016 – – TheProductLawyers.com comments on news that a warning to the public regarding a new-generation type-2 diabetes drug named Invokana has been given by the U.S. Food and Drug Administration (FDA). The SGLT2 class inhibitor drug was manufactured by pharmaceutical giant Johnson & Johnson’s subsidiary, Janssen Pharmaceuticals to assist type-2 diabetes patients to maintain safe blood sugar levels by preventing the kidneys from reabsorbing excess sugar and instead using the organs to excrete from the body excess sugar through urination.

However, adverse event reports filed with the FDA have allegedly linked Invokana (Canagliflozin) to the potentially fatal condition, diabetic ketoacidosis. This occurs when high levels of toxic acids, (ketones) are retained in the bloodstream. This is the basis of the warning given to consumers.

The FDA has instructed those patients currently using the drug to be alert to any signs or symptoms that the dangerous condition may be developing. Amongst the symptoms listed are nausea with vomiting, extreme fatigue, mental confusion, breathing difficulty and pain within the abdominal region. As untreated diabetic ketoacidosis can result in death, the FDA is urging patients using Invokana to seek urgent medical attention if they are experiencing any of these symptoms.

The agency has indicated that at this time, they have received around 20 reports of patients developing diabetic ketoacidosis after using Invokana. All required hospitalization to treat the condition. Reportedly, most of the patients involved had used Invokana for only approximately two weeks time before they began to suffer from serious symptoms. Diabetic ketoacidosis which developed in patients using Invokana has also been the subject of several recently filed lawsuits against Janssen.

The FDA will continue to further investigate has noted the potential links discovered. During their announcement, they stated, “We are continuing to investigate this safety issue and will determine whether changes are needed in the prescribing information for this class of drugs.”

For more information about the Invokana lawsuits, or this press release, please contact TheProductLawyers.com on 888-997-3792.

###

Contact TheProductLawyers.com:

Banville Law
888-997-3792
info@banvillelaw.com
165 West End Ave #1h,
New York, NY 10023

ReleaseID: 60009586